Heat-stable carbetocin and tranexamic acid for postpartum hemorrhage prevention and treatment in basic emergency obstetric care facilities in fragile and humanitarian settings in South Sudan and Uganda
Not Applicable
Recruiting
- Conditions
- Pregnancy and Childbirth
- Registration Number
- PACTR202302476608339
- Lead Sponsor
- FPA Humanitarian Division
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 1008
Inclusion Criteria
A woman will be eligible to participate in the study after she has
(1) given birth at the facility and
(2) provided informed consent (which will be done during the postpartum period before her discharge from the facility). Adult participants will give their informed consent. Non-adult participants will give their informed assent and their respective parents or guardians their informed consent.
Exclusion Criteria
(1) has not given birth at the facility
(2) has not provided informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) proportion of birthing women receiving a uterotonic for PPH prevention. This overall proportion will be broken down by type of uterotonics that are available (e.g., oxytocin, misoprostol) or will be made available (HSC) in facilities; ;(2) proportion of women with clinical PPH receiving a uterotonic for PPH treatment (e.g., oxytocin, misoprostol);
- Secondary Outcome Measures
Name Time Method (3) proportion of women with clinical PPH receiving TXA for PPH treatment.